The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown. METHODS: We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor. RESULTS: A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose. CONCLUSIONS: In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of these benefits were consistent regardless of presence or absence of ASCVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondary analyses across several of these trials also showed that HF prevention benefits of SGLT2is are present regardless of baseline CV or antihyperglycemic therapies (including metformin) (Fig. 5).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, there was also a modest but significant 10% reduction in the risk of MACE (HR, 0.90; 95% CI, 0.85–0.95).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (309,312).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the relatively small percentage of such individuals enrolled (only 21% of participants had ejection fraction >50%) and the early termination of the trial limited the ability to determine the effects of sotagliflozin in HFpEF specifically (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (296,298).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The studies that led to the approved indication for heart failure (HF) excluded individuals with type 1 diabetes or a history of DKA (82,83).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [82]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sotagliflozin significantly reduced the risk of achieving the primary end point of CV death, HHF, or urgent visit for HF (51.0 vs 76.3 events per 100 patient-years; HR, 0.67 [95% CI 0.52-0.85]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“There was no signi fi cant interaction by eGFR status for the primary outcome.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“sotaglifl ozin did reduce the primary outcome by 33% (HR: 0.67; 95% CI: 0.52 -0.85).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“In the SOLOIST trial, sotagliflozin initiated during or shortly after hospitalization in people with diabetes also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“ultimately no evidence of heterogeneity of treatment effect by ejection fraction was noted.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“In the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial, sotagliflozin, a combined SGLT1/2 inhibitor, initiated during or shortly after hospitalization for heart failure in people with diabetes, also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
In the citing paper
“Canagliflozin, Dapagliflozin, Sotagliflozin significantly decrease the composed primary end-point, including cardiovascular mortality and other cardiovascular outcomes [10,11,12].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [12]
In the citing paper
“Sotagliflozin reduced the risk of the primary composite outcome of CV death, HF hospitalization, and urgent visit for HF by 33%, with a consistent effect across the spectrum of baseline LVEF.However, the number of events in the HFpEF group was too small to draw any firm conclusion.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sotagliflozin significantly reduced the RR of the composite primary outcome (CV death, HF hospitalization, or urgent visit for HF) by 33% compared with placebo (HR 0.67; 95% CI, 0.52-0.85).The treatment effect was consistent across the spectrum of LVEF.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sub-group analyses considering those co-prescribed MRA and SGLT2 inhibitors suggest their combined use does not modify safety findings from the key trials.150,189,[722][723][724][725][726]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“However, the relatively small percentage of such patients enrolled (only 21% of participants had ejection fraction > 50%) and the early termination of the trial limited the ability to determine the effects of sotagli fl ozin in HFpEF speci fi cally.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“No signi fi cant between-group differences were found in the rates of cardiovascular death or all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“At a median follow-up of 9 months, the rate of primary end point events (the total number of cardiovascular deaths and hospitalizations and urgent visits for heart failure) was lower in the sotaglifl ozin group than in the placebo group (51.0 vs. 76.3; HR 0.67 [95% CI 0.52 -0.85]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Flagged first, then by citations
Research works printed but not linked: 1
- Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2015;132(15):e198-e198.26459088
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Escobar, C., Palacios, B., Gonzalez, V., Gutiérrez, M., Duong, M., Chen, H., Justo, N., Cid-Ruzafa, J., Hernández, I., Hunt, P. R., et al. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-10376-z · Cited by 8
Soleimani, H., Saeedian, B., Pasebani, Y., Babajani, N., Pashapour‐Yeganeh, A., Bahiraie, P., Navid, H., Amin, A., Samsky, M. D., Nanna, M. G., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14633 · Cited by 8
When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
Badwan, O. Z., Braghieri, L., Skoza, W. A., Agrawal, A., Menon, V., & Tang, W. H. W. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23034 · Cited by 8
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
Kondo, T., Mogensen, U. M., Talebi, A., Gasparyan, S. B., Campbell, R. T., Docherty, K. F., de Boer, R. A., Inzucchi, S. E., Køber, L., Kosiborod, M., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.385 · Cited by 8
Kim, J., Wang, S.-S., Sikirica, S., & Shafrin, J. (2023) · medRxiv · doi:10.57264/cer-2023-0190 · Cited by 6
Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review
Nikolaidou, A., Ventoulis, I., Karakoulidis, G., Anastasiou, V., Daios, S., Papadopoulos, S.-F., Didagelos, M., Parissis, J., Karamitsos, T. D., Kotsa, K., et al. (2024) · Medicina · doi:10.3390/medicina60060912 · Cited by 9
Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF
Weintraub, W. S., Kolm, P., Dolman, S. F., Alva, M. L., Bhatt, D. L., & Zhang, Z. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.018 · Cited by 8
Self-citationNovel Therapies to Reduce Rehospitalization Risk in Worsening Heart Failure
Lima, I. G. C. V., Nunes, J. T., Godoy, L. C., McDonald, M., & Bocchi, E. A. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101451 · Cited by 8
Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults
Hashemi, A., Kwak, M. J., & Goyal, P. (2025) · Drugs & Aging · doi:10.1007/s40266-024-01165-2 · Cited by 8
Berg, D. D., Patel, S. M., Haller, P. M., Bělohlávek, J., Desai, A. S., Dróżdż, J., Inzucchi, S. E., McMurray, J. J. V., Merkely, B. P., O’Meara, E., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.014 · Cited by 8
Self-citationKapelios, C. J., Canepa, M., Savarese, G., & Lund, L. H. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2214 · Cited by 8
Self-citationHitchen, S. A., Lan, N. S. R., Ali, U., Hort, A. L., Larbalestier, R. I., Yeap, B. B., & Fegan, P. G. (2021) · Internal Medicine Journal · doi:10.1111/imj.15393 · Cited by 8
SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
Chen, H., Birnbaum, Y., Ye, R., Yang, H., Bajaj, M., & Ye, Y. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07243-6 · Cited by 9
Fucili, A., Cimaglia, P., Severi, P., Giannini, F., Boccadoro, A., Micillo, M., Rapezzi, C., Tavazzi, L., & Ferrari, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194325 · Cited by 8
The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
Fadiran, O., & Nwabuo, C. C. (2021) · Cureus · doi:10.7759/cureus.19379 · Cited by 8
Camilli, M., Lombardi, M., Chiabrando, J. G., Zito, A., Buono, M. G. D., Vergallo, R., Aspromonte, N., Lombardo, A., Montone, R. A., Niccoli, G., et al. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001452 · Cited by 8
Usman, M. S., Khan, M. S., Fonarow, G. C., Greene, S. J., Friede, T., Vaduganathan, M., Filippatos, G., Coats, A. J. S., Anker, S. D., & Butler, J. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13785 · Cited by 8
Villevalde, S. V., & Soloveva, A. E. (2021) · Kardiologiia · doi:10.18087/cardio.2021.12.n1860 · Cited by 8
Schechter, M., Fischer, M., & Mosenzon, O. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14675 · Cited by 8
Lioudaki, E., Joslin, J. R., Trachanatzi, E., & Androulakis, E. S. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303082 · Cited by 8
Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?
Mukhopadhyay, P., Sanyal, D., Chatterjee, P., Pandit, K., & Ghosh, S. K. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.05.005 · Cited by 8
Greene, S. J., Lautsch, D., Gaggin, H. K., Djatche, L. M., Zhou, M., Song, Y., Signorovitch, J., Stevenson, A. S., Blaustein, R. O., & Butler, J. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.016 · Cited by 8
Delgado, E., Jódar, E., Mezquita‐Raya, P., & Moreno, Ó. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01278-0 · Cited by 8
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
Rhee, E. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.304 · Cited by 9
Kurczyński, D., Hudzik, B., Jagosz, M., Zabierowski, J., Nowak, J. U., Tomasik, A. R., Bądziński, A., Rozentryt, P., & Gąsior, M. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9070225 · Cited by 9
Al‐Salameh, A., Bouzegaoui, N. E., & Saraval, M. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.09.023 · Cited by 11
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction
Rastogi, T., & Girerd, N. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.006 · Cited by 8
Safety of sodium–glucose c otransporter 2 inhibitors in Asian type 2 diabetes populations
Davidson, J. A., Sukor, N., Hew, F., Mohamed, M., & Hussein, Z. B. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13915 · Cited by 8
Hasan, M. T., Awad, A. K., Shih, M., Attia, A. N., Aboeldahab, H. A., Bendary, M. M., & Bendary, A. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.027 · Cited by 8
Brust-Sisti, L. A., Rudawsky, N., Gonzalez, J., & Brunetti, L. (2022) · Pharmacy · doi:10.3390/pharmacy10060166 · Cited by 9
Becher, P. M., Savarese, G., Benson, L., Dahlström, U., Karlström, P., Mol, P. G. M., Metra, M., Bhatt, D. L., Pitt, B., & Lund, L. H. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad012 · Cited by 8
Self-citationAntihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)
Clodi, M., Abrahamian, H., Brath, H., Schernthaner, G., Brix, J., Ludvik, B. H., Drexel, H., Saely, C. H., Fasching, P., Rega‐Kaun, G., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02186-4 · Cited by 8
Harrington, J., Sun, J., Fonarow, G. C., Heitner, S. B., Divanji, P., Binder, G., Allen, L. A., Alhanti, B., Yancy, C. W., Albert, N. M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028820 · Cited by 8
Cotter, G., & Davison, B. A. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2916 · Cited by 8
Cotter, G., Davison, B. A., Adams, K. F., Ambrosy, A. P., Atabaeva, L. S., Beavers, C. J., Bhatt, A. S., Givertz, M. M., Grodin, J. L., Lala, A., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3109 · Cited by 8
Self-citationVaduganathan, M., Greene, S. J., Zhang, S., Solomon, N. C., Chiswell, K., DeVore, A. D., Butler, J., Heidenreich, P. A., Huang, J., Kittleson, M. M., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.11.010 · Cited by 8
Ostrominski, J. W., & Vaduganathan, M. (2022) · Clinical Cardiology · doi:10.1002/clc.23849 · Cited by 9
Cardioprotection with Yet Another SGLT2 Inhibitor — An Embarrassment of Riches
Brosius, F. C., & Vandvik, P. O. (2021) · New England Journal of Medicine · doi:10.1056/nejme2033176 · Cited by 8
von Haehling, S., Sato, R., Butler, J., & Anker, S. D. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2766 · Cited by 8
Kao, Y., Chao, T., Chen, S., Cheng, Y., Chan, Y., & Chu, P. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033236 · Cited by 7
Butler, J., Shah, S. J., MAGWIRE, M. L., Campos, C., Usman, M., Hoovler, A., Sabharwal, A. K., & Borlaug, B. A. (2024) · Global Cardiology · doi:10.4081/cardio.2024.38 · Cited by 7
Lanier, C., Brumit, J. C., Tharp, J. L., Crawford, J., White, K. M., Wilson, V., & Covert, K. L. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf025 · Cited by 7
Chandan, N., Ashok, V., Hwang, T., Lim, V. G., Lachlan, T., Eftekhari, H., McGregor, G., & Osman, F. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm27175 · Cited by 7
Mazzotta, R., Garofalo, M., Salvi, S., Orlandi, M., Marcaccini, G., Susini, P., Checchi, L., Palazzuoli, A., Mario, C. D., Pieroni, M., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15293 · Cited by 7
Liu, B., Jin, Q., Sun, Y., Yang, Z. M., Meng, P., Zhang, X., Chen, Q., Gan, P., Zhao, T., He, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1563362 · Cited by 7
Fu, C., Deng, L., Zhu, X., Wang, B., Hu, B., Xue, H., Zeng, Q., & Zhang, Y. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100846 · Cited by 7
Parsi, S., Shirsat, P. D., Mahali, L. P., Surani, S., & Kashyap, R. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i10.109731 · Cited by 7
Dong, H., Chang, L., Tian, T., Shi, R., Yu, K., Wang, C., Liu, Z., Jin, Q., Wang, J., He, T., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1724965 · Cited by 7
Daniyal, M., Khatoon, N. M., Rasool, A., Gul, I., Tabish, S., Asifa, S., Khalid, A., Aftab, Z., Burhan, M., Fahim, S. L., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70184 · Cited by 7
Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors
Chrysant, S. G., & Chrysant, G. S. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2057949 · Cited by 7
Requena-Ibáñez, J. A., Santos‐Gallego, C. G., & Badimón, J. J. (2022) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2022.04.019 · Cited by 7
Du, L., Qin, J., Wang, D., Zhao, Y., Xu, N., Wu, C., & Yuan, J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1028486 · Cited by 7
Bose, D., Maurya, M. R., & Konwar, M. (2023) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_342_21 · Cited by 7
Jhund, P. S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15171 · Cited by 7
Ghosal, S., & Sinha, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168755 · Cited by 7
Bánfi‐Bacsárdi, F., Vámos, M., Majoros, Z., Török, G., Pilecky, D., Duray, G. Z., Kiss, R. G., Nyolczas, N., & Muk, B. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32836 · Cited by 7
Hammer, A., Niessner, A., & Sulzgruber, P. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07512-6 · Cited by 7
Hua, T., Chu, Y., Wang, M., Zhang, Y., Shi, W., Huang, Q., Zhang, L., & Yang, M. (2023) · Intensive Care Medicine Experimental · doi:10.1186/s40635-023-00562-y · Cited by 7
Natriuretic peptide testing strategies in heart failure: A 2023 update
Chaikijurajai, T., Rincon-Choles, H., & Tang, W. H. W. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.11.005 · Cited by 7
Khayari, A. E., Hakam, S. M., Malka, G., Rochette, L., & Fatimy, R. E. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101174 · Cited by 7
Kuo, H., Lai, Y., Lin, P., Chen, H.-H., Hung, C., Liu, L. Y., & Yeh, C.-K. (2023) · Scientific Reports · doi:10.1038/s41598-023-48716-y · Cited by 9
Zheng, Z., Chen, X., Zhang, Y., Zhang, Y., Wang, K., Shi, Z., Yang, X., Yuan, F., & Liu, J. (2023) · Neurotherapeutics · doi:10.1016/j.neurot.2023.11.002 · Cited by 7
Olivella, A., Bonet, L. A., Moliner, P., Coloma, E., Martínez‐Rubio, A., Bermejo, M. P., Boixeda, R., Cediel, G., Méndez, A. B., & Fácila, L. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14647 · Cited by 7
Wang, Y., & Zhou, X. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03631-7 · Cited by 7
The effect of the four pharmacological pillars of heart failure on haemoglobin level
Hullon, D., Taherifard, E., & AlSaraireh, T. H. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001773 · Cited by 7
Palm, C. L., SHALAUROVA, I. Y., Connelly, M. A., Bakker, S. J. L., Westenbrink, B. D., & Dullaart, R. P. F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061541 · Cited by 7
Felix, N. S., Gauza, M. D. M., Teixeira, L., Guisso, M. E. S., Nogueira, A., Dagostin, C. S., Godoi, A., Ribeiro, S. A. G., Duque, J. C., Moura-Neto, J. A., et al. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2023.0241 · Cited by 7
Vaduganathan, M., Cannon, C. P., Jardine, M., Heerspink, H. J. L., Arnott, C. G., Neuen, B. L., Sarraju, A., Gogate, J. P., Seufert, J., Neal, B. C., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3292 · Cited by 7
Self-citationWu, D., Ma, Z., Wang, X., Wang, X., & Wang, X. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04078-5 · Cited by 7
Sotoudeheian, M., Mirahmadi, S., Darjani, P. S., Moradi, M., Pirhayati, M., Dakkali, M. S., Taghizadeh, M., Azarbad, R., & Pazoki–Toroudi, H. (2025) · Diabetology International · doi:10.1007/s13340-025-00800-6 · Cited by 7
Pagidipati, N. J., & DEEDWANIA, P. C. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.04.024 · Cited by 7
Gliflozine – in Zukunft Kardioprotektiva?
Rauch‐Kröhnert, U., & Landmesser, U. (2021) · Der Internist · doi:10.1007/s00108-021-01083-0 · Cited by 8
Silva‐Cardoso, J., Fonseca, C., Franco, F., Morais, J., Ferreira, J., & Brito, D. A. (2021) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2021.07.009 · Cited by 7
Lin, C., Cai, X., & Ji, L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14596 · Cited by 7
Lam, B. C. C., Chew, D. P., & Pasquale, C. G. D. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.12.015 · Cited by 7
Maitra, N. S., Mahtta, D., Navaneethan, S. D., Vaughan, E. M., Kochar, A., Gulati, M., Levine, G. N., Petersen, L. A., & Virani, S. S. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01694-5 · Cited by 7
Mazin, I., Chernomordik, F., Fefer, P., Matetzky, S., & Beigel, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071904 · Cited by 8
Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy
Murphy, D., & Banerjee, D. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00552-3 · Cited by 7
López‐Vilella, R., Trenado, V. J. D., Cervera, B. G., Sánchez-Lázaro, I. J., & Bonet, L. A. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.06.008 · Cited by 7
Chan, Y., Chao, T., Chen, S., Kao, Y., Huang, C.-Y., & Chu, P. (2022) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcac040 · Cited by 7
Cheng, J. W. M., Colucci, V. J., Kalus, J. S., & Spinler, S. A. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231154021 · Cited by 7
SGLT2 Inhibitor: an Emerging Pillar in Heart Failure Therapeutics?
GEAVLETE, B. F., Popescu, R.-I., Iordache, V., Georgescu, D. E., & Geavlete, P. A. (2023) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2023.18.1.102 · Cited by 7
Avgerinos, I., Karagiannis, T., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15200 · Cited by 8
Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c
Aggarwal, R., Bhatt, D. L., Szarek, M. J., Cannon, C. P., McGuire, D. K., Inzucchi, S. E., Lópes, R. D., Davies, M. J., Banks, P. L., Pitt, B., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.050 · Cited by 7
Self-citationChee, Y. J., & Dalan, R. (2024) · Biomedicines · doi:10.3390/biomedicines12071386 · Cited by 7
Singh, A. K., Singh, R., & Misra, A. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13182 · Cited by 7
Jain, V., Rifai, M. A., Mahtta, D., Liu, J., Hussain, A., & Virani, S. S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00952-1 · Cited by 7
Koufakis, T., Papazafiropoulou, A. K., Makrilakis, K., & Kotsa, K. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07249-0 · Cited by 7
SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction
Hias, J., Hellemans, L., Walgraeve, K., Tournoy, J., & der Linden, L. R. V. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00920-7 · Cited by 7
Dhalla, N. S., Bhullar, S. K., & Shah, A. K. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0154 · Cited by 7
Pitt, B., & Epstein, M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2441 · Cited by 7
Self-citationEffect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation
Chen, S., Ou, W., Gan, S., Chen, L., Liu, B., & Zhang, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1523727 · Cited by 7
Ge, J. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000112 · Cited by 6
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 6
Milhem, F. S., Almur, O., Hajjeh, O., Bdair, M., Dahmas, A. M., Haddad, K. B., Shubietah, A. R. M., Al-Said, O. S., Al-Braik, R., Abukhalil, M. M., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003592 · Cited by 6
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 6
Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes
Katsiki, N., Kazakos, K., & Triposkiadis, F. K. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2143263 · Cited by 6
González, O. E. O., Mejía, D. C. L., Kaplinsky, E., Barbagelata, A., & Perrone, S. V. (2023) · Drugs in Context · doi:10.7573/dic.2022-6-4 · Cited by 6
Li, R., Dai, G., Guan, H., Gao, W., Ren, L., Wang, X., & Qu, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1143658 · Cited by 6
Montero-Pérez-Barquero, M., Escobar, C., Arévalo‐Lorido, J. C., Martel, A. C., Salamanca‐Bautista, P., Manzano, L., Formiga, F., Díez‐Manglano, J., Cepeda, J. M., Franco, Á. G., et al. (2023) · Future Cardiology · doi:10.2217/fca-2023-0016 · Cited by 6
Metadata
- Authors
- Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Wilcox, C. S., Ponikowski, P., Lopes, R. D., Verma, S., Lapuerta, P., & Pitt, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 117-128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3100542962
- Semantic Scholar
- a022df46be992be653dc8f2439f324470b7eb318
- Cited by
- 1,868
- References
- 51
- Citations by year
- 2026: 160 · 2025: 231 · 2024: 316 · 2023: 373 · 2022: 409 · 2021: 355
- FWCI
- 178.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Sanofi
- Lexicon Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sotagliflozin, SGLT2 inhibitors, type 2 diabetes, worsening heart failure, acute decompensated heart failure, heart failure hospitalization, cardiovascular mortality, diarrhea, hypoglycemia, drug safety, DAPA-HF
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycosides, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Sodium-Glucose Transporter 1, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
